NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 145)
Posted On: 01/13/2023 2:55:04 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needs
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently announced statistically significant (p<0.001) efficacy results in a preclinical in-vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “The study concluded that compared to pre-infection weight, the control group’s weight declined on average at 12.01%. In contrast, on average, the weight of the experimental group using BiondVax’s NanoAb therapy declined only 3.80%. The successful result of the study was further supported by eight other tracked parameters, including heart rate and social behaviors, indicating that the group treated with NanoAbs experienced a milder, shorter illness,” a recent article reads. “BiondVax is developing a pipeline of alpaca-derived NanoAb therapies to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, psoriatic arthritis, and macular degeneration. Compared with current monoclonal antibodies (‘mAbs’) treatments, BiondVax’s NanoAbs exhibit strong potential for superior patient convenience, safety and clinical outcomes, at a lower cost.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently announced statistically significant (p<0.001) efficacy results in a preclinical in-vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “The study concluded that compared to pre-infection weight, the control group’s weight declined on average at 12.01%. In contrast, on average, the weight of the experimental group using BiondVax’s NanoAb therapy declined only 3.80%. The successful result of the study was further supported by eight other tracked parameters, including heart rate and social behaviors, indicating that the group treated with NanoAbs experienced a milder, shorter illness,” a recent article reads. “BiondVax is developing a pipeline of alpaca-derived NanoAb therapies to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, psoriatic arthritis, and macular degeneration. Compared with current monoclonal antibodies (‘mAbs’) treatments, BiondVax’s NanoAbs exhibit strong potential for superior patient convenience, safety and clinical outcomes, at a lower cost.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links
Scroll down for more posts ▼